Environment matters.

Just as the environment matters at the macro scale for plants and animals, it is essential at the micro scale for cells. Recognizing the importance of the native cellular microenvironment, Xylyx Bio is harnessing the power of tissue-specific extracellular matrix, the body’s native cell environment, for both drug discovery and tissue regeneration.

Cell Culture

Xylyx Bio's suite of native tissue-specific extracellular matrix (ECM) products bring the most physiologic cell environments possible to the petri dish to radically improve early-stage drug discovery efforts.

Tissue Regeneration

With potential to address multiple unmet clinical needs, Xylyx Bio is utilizing its proprietary matrix bioactives to pursue R&D on clinically-oriented products derived from tissue-specific ECM.


Xylyx Bio and Cell&Soft Announce Strategic Partnership to Develop Next-Generation Cell Culture Platforms to Accelerate Cancer Drug Discovery

New  York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.

Read More

Webinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform

Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment. In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present […]

Read More

Webinar: Redefining cancer research with IN SITE™ Metastasis Kit

Metastasis is the dissemination of cancer cells to distant organs: bone, liver, and lung being the most common sites of metastasis. The lack of in-vitro models that recapitulate the tissue-specific extracellular matrix (ECM) in metastatic sites presents a significant barrier for better understanding the mechanisms driving tumor colonization and consequently to developing drugs that effectively […]

Read More

Xylyx Bio releases advanced disease model system to improve cancer drug discovery

More faithful representation of disease biology is key to identify drivers of metastasis and targets for therapeutic intervention. Xylyx Bio’s IN SITE™ Metastasis Kit incorporates native tissue bone, liver, and lung extracellular matrices to provide key features of site-specific microenvironments, allowing scientists to more accurately model cancer metastasis in common secondary sites.

Read More

What they’re saying